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1. Introduction
Maspin (mammary serine protease inhibitor, serpin B5) 
is a serine protease inhibitor in the serine superfamily 
(1). Serine protease inhibitors are a large protein family 
related to inflammation, apoptosis, angiogenesis, and 
embryogenesis (2). Maspin is an intracellular protein that 
can dissolve in cytoplasm and can be found in different 
locations in the cell (3). The varied locations are important 
because abnormal localization in some tissues indicates 
neoplasia. For instance, whereas maspin in cytoplasm is 
associated with a poor prognosis, maspin in the nucleus is 
associated with benign lesions (2,3).
Maspin has been studied in many organs in the body (1–
4). Most studies are related to prostate cancer in urology. A 
high rate of maspin release was shown in normal prostate 
epithelium cells. However, maspin release decreased in 
cells with prostate cancer and disappeared in metastases 
(4,5). Researchers have suggested that maspin positivity in 
prostate and lung cancer had an apoptosis-like effect (6). In 
a study carried out on renal tumors, cytoplasmic staining 
of maspin in kidney tumors was shown, and in renal 
cell carcinomas, the decrease in maspin expression was 
correlated with tumor growth and advanced pathologic 
stage. Therefore, the decrease in maspin expression was 
thought to be associated with a poor prognosis (7).
No detailed study related to maspin and the testes 
(normal testis tissue or tumors) has been published in the 
literature. Only two studies gave brief information about 
the fact that there is maspin expression in testis tissue 
(8,9). No studies have shown a relation between maspin 
and testicular tumors. In this study, the presence of maspin 
expression in the testis and the effects of maspin protein 
on tumor progression were evaluated, and its relation with 
angiogenesis factors such as vascular endothelial growth 
factor (VEGF), p53, Ki-67, and thrombocyte endothelium 
adhesion molecule-1 (PCAM-1 or CD31) was examined.
Background/aim: We aimed to evaluate the importance of maspin expression in testicular tumors with germ cells, its effect on prognosis, 
and the relation with angiogenesis factors. 
Materials and methods: The paraffin blocks of the orchiectomy materials of 32 patients who had undergone orchiectomy due to 
testicular tumors were taken within the scope of the study. The specimens of the cases included in the study group were reexamined 
under light microscope.  
Results: While just one maspin-positive sample was found in the seminoma cases, maspin stained positively in 6 of the nonseminoma 
germ cell tumors (NSGCTs). No statistical difference was found between maspin and tumor stage, size, alpha fetoprotein values, 
vascular endothelial growth factor, Ki-67, and CD31. A statistically positive correlation was only determined between maspin and p53 
(P < 0.001). 
Conclusion: Maspin protein, whose expression in some tumors is accepted as a poor prognostic factor, is also expressed in testicular 
tumors with germ cells. However, according to our study, it is difficult to say whether this protein is a favorable or poor prognostic 
factor in testicular tumors and to understand how the effect mechanism works. The positive correlation between maspin and p53 in the 
NSGCTs makes us think that maspin might have displayed an effect on the p53 pathway.
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2. Materials and methods
Paraffin blocks in the archives of the Başkent University 
Faculty of Medicine’s Department of Pathology, comprising 
orchiectomy material from 32 patients diagnosed with a 
germ cell tumor (GCT) after they had undergone radical 
(inguinal) orchiectomy due to testis tumors, were used in 
this study. The study was approved by the Başkent University 
ethics committee. Sections from the paraffin blocks of 5 
µm that included the entire tumor (seminomatous and 
nonseminomatous tumor areas were separated in mixed 
germ cell tumors) were prepared, and the sections were 
put on polylysine slides. CD-31 (Biocare, REF-CM347A, 
LOT101209-R1, 1/300 dilution), Ki-67 (Spring, Clone 
D0-7, RTU), and maspin (Lifespan, LOT# 18780, 1/50 
dilution) primary antibodies were applied with a standard 
immunohistochemical staining procedure. The specimens 
were then screened under a light microscope. Brown-orange 
staining was accepted as positive owing to the chromogen 
used.
The mean age of the 32 GCT patients was 30.3 years 
(between 19 and 63). After the patient files were reexamined 
and the age and preoperative human chorionic gonadotropin 
(hCG) and alpha fetoprotein (AFP) values were obtained 
from the pathology reports and samples stained with 
hematoxylin and eosin, data on the histological type, 
tumoral mass size, tumor stage, lymphovascular invasion, 
rete testis stiffness, and lymph node stiffness were collected. 
The comparisons and statistical analyses were performed 
using the prognostic factors in the European Association of 
Urology’s (EAU) testicular tumor guidelines (10).
2.1. Histopathologic evaluation 
The positive staining pattern of the maspin protein was 
examined in the nucleus and cytoplasm of the tumor 
cells: cytoplasmic staining for VEGF and nuclear staining 
for p53. No nuclear staining was detected with maspin 
in any material. Positivity was assessed as 0 (1%–5% cells 
positive), + (6%–50% cells positive), and ++ (51%–100% 
cells positive). The positively stained cell count rate was 
calculated in approximately 1000 tumor cells in five large 
magnification areas for Ki-67 (5-HPF, 400× magnification). 
CD-31 was calculated by eliciting the average number of 
veins in five large magnification areas.
2.2. Statistical analyses 
In the statistical assessment of the results, SPSS 14.0 was 
used. To examine correlations, Pearson correlation analysis 
was used; to test the significance of different series, Fisher’s 
exact test (with two methods) was used; and to compare 
the groups, one-way ANOVA was applied. The results were 
accepted as statistically significant at P < 0.05.
3. Results
The distribution of the cases according to tumor stages 
was T1: 15, T2: 12, T3: 1, and T4: 4. Fourteen patients had 
pure seminomas, 18 patients had nonseminoma germ cell 
tumors (NSGCTs), only one had embryonal carcinoma, 
and the rest had mixed components. The maspin-
positive staining pattern was examined in tumor cells in 
the cytoplasm and the nucleus. No nuclear staining was 
detected. Although only 1 out of 14 seminoma cases was 
positive for maspin, 6 out of 18 NSGCTs were positive for 
maspin (Figures 1A and 1B). The stages were evaluated 
in terms of maspin positivity by setting up binary groups 
among them, and no difference was detected statistically 
between the stages. The P-values were T1–T2, P = 0.05; 
T1–T4, P = 0.39; and T2–T4, P = 0.18. No further statistics 
were produced since there was only 1 patient with aT3 
stage tumor. The patients’ tumor sizes were separated 
into two groups: ≤4 cm and ≥4 cm. The relation between 
maspin and tumor size was assessed for the two groups. No 
statistical correlation was detected (P > 0.05). Serum AFP 
and HCG values of the mixed GCT cases were studied. 
All patients’ HCG values were below 5000 mIU/mL when 
classified in accordance with the EAU guidelines. Although 
the AFP values for 14 AFP-positive patients were below 
1000, in two patients, the values were between 1000 and 
10,000, and in one patient, the value was above 10,000. The 
statistical analysis showed no correlation between maspin 
positivity and AFP (P > 0.05).The patients’ HCG values 
were below 5000 mIU/mL, and no statistically significant 
relation was determined between maspin positivity and 
HCG.
The positive staining pattern for VEGF was accepted as 
cytoplasmic positive staining in tumor cells. In 8 cases of 
seminomas, less than 5% staining occurred or no staining 
took place at all. In the cases of NSGCTs, in 11 patients, 
there was more than 50% (2+) staining. No significant 
relation was detected between maspin and VEGF in 
patients with seminomas (P > 0.05). Similarly, no relation 
was determined between maspin and VEGF in NSGCTs 
(P > 0.05).
In p53 evaluation, the positive staining pattern was 
nuclear (Figures 1C and 1D). In 3 seminoma cases, p53 
stained positively in more than 50% of the cells; however, 
more than 50% staining occurred in 10 of the NSGCT 
cases. No staining occurred in one seminoma case. This 
was the only maspin-positive case among the seminomas. 
No statistically significant difference was detected between 
maspin and p53 in cases of seminoma (P > 0.05). In the 
statistical analysis conducted on NSGCTs, there was a 
positive correlation between maspin and p53 (P < 0.001).
In the evaluation of Ki-67, the positive staining pattern 
was nuclear positive staining in tumor cells. There was 
35.6% staining in the seminomas while there was 50.1% 
staining in the NSGCTs. No statistical connection was 
established between maspin and Ki-67 in the seminoma 
cases (P > 0.05). The relation between maspin and Ki-67 
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was statistically insignificant in the NSGCTs (P > 0.05).
In CD31 evaluation, the mean vein count was 
calculated in five large magnification areas (5-HPF, 
400× magnification). The mean CD31 of the seminoma 
cases was 12.2, whereas the mean CD31 of the 
nonseminomatous cases was 8.8. No statistical difference 
was found between maspin and CD31 in either seminoma 
or nonseminomatous tumors (P > 0.05).
4. Discussion
Maspin, which was first discovered in breast tissue and 
breast cancer cell lines with the hybridization procedure, 
is decreased in invasive and metastatic breast and prostate 
cancers (1,2). The tumor suppressor function of maspin 
was shown in in vitro studies. Unlike cell adhesion and 
other serpins, maspin leads to an increase in apoptosis and 
a decrease in cell motility, angiogenesis, and pericellular 
proteolysis (1,4). In some experimental studies, maspin 
prevented the development and/or progression of 
malignant tumors with the p53-dependent pathway, 
plasminogen activation inhibition, and angiogenesis 
inhibition (11). Studies also suggested that maspin takes 
effect through angiogenesis and is associated with VEGF 
(12). High maspin expression was shown in normal 
human breast and prostate epithelium cells. However, 
expression decreased in the cancer cells of these organs 
and disappeared in metastases (3–5). Other studies 
suggested that increased maspin expression was a good 
prognostic factor in oral squamous cell carcinomas (4). 
In contrast, increased maspin expression was detected in 
pancreas-origin cancers, whereas no maspin expression 
was observed in normal pancreas cells (11).
Various reports have suggested that nuclear 
and cytoplasmic maspin expression has different 
clinicopathologic importance in different types of tumors. 
That nuclear positivity was a good prognostic indication 
was emphasized in some studies, while in others maspin 
positivity was associated with shorter-term survival. 
Sood et al. reported that cytoplasmic localization was 
related to a poor prognosis, whereas nuclear localization 
was associated with benign cases in ovarian cancers (3). 
In a study conducted on adenocarcinomas, improved 
Figure 1. Cytoplasmic brown staining positivity in embryonal carcinoma (A) and seminoma (B) areas and nuclear brown 
staining positivity in embryonal carcinoma (C) and seminoma (D) areas for p53.
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morphologic indications were found in patients who 
showed nuclear maspin positivity (13). Nakagawa et al. 
did not determine a difference between maspin-positive 
and -negative groups in terms of prognosis (11). However, 
the researchers suggested that cytoplasmic-stained maspin 
was a good prognostic factor in renal tumors (7). Maspin 
positivity was present in only 1 out of 14 seminoma cases 
and 6 out of 18 NSGCT cases in our study. All maspin-
positive cases were cytoplasmically stained, and no 
nuclear staining was observed in any tumors. Due to the 
small number of positively stained tumor cells, it is hard 
to say whether cytoplasmic staining is an indication of 
a good or bad prognosis. Perhaps different subforms 
(active or inactive) of maspin, which was detected 
immunohistochemically in the cytoplasm, could exist 
at the molecular level, and these forms might reveal the 
behavior of maspin in tumors.
Maspin positivity in NSGCTs was significantly higher 
than in the seminoma group in our study. Prognosis 
for NSGCTs was worse than that for seminomas. No 
connection was observed between maspin and tumor 
stage, tumor size, or AFP level. Thus, maspin is not a 
predictor of a bad prognosis in testicular tumors, but the 
fact that it exists more in NSGCTs is an important subject 
that should be investigated in wider chain studies.
Along with tumor angiogenesis, VEGF functions as 
an autocrine and paracrine growth factor that induces 
the proliferation of tumor cells. A connection between 
VEGF levels and metastases and/or bad prognosis was 
found in many tumors within the body (12–14). Studies 
in the literature regarding VEGF and testicular tumors are 
lacking. VEGF expression was shown to be significantly 
higher in testicular tumors in a study carried out by Fukuda 
et al. and in multivariate analyses it was reported that 
VEGF displayed significant correlation with metastases 
development, especially in seminomas (15). The high 
percentage of VEGF staining in our study agreed with the 
findings in the literature. Although studies have indicated 
a significant relation between maspin and angiogenesis, 
this relation was not observed in our study. Likewise, no 
relation was discovered between maspin and VEGF in a 
previous study conducted on renal tumors (7). Maspin, as 
is the case with renal tumors, may have had an effect at the 
cellular level with a nonangiogenesis mechanism different 
from other tumor groups. Ki-67 is a proliferation kinetics 
index used to determine the correct histopathologic 
diagnosis, prognosis, and treatment approaches in many 
malignant tumors (16). 
The Ki-67 index in germ cell tumors in testes is used 
to determine a patient’s risk group. Düe et al. investigated 
the Ki-67 antibody and the growth pattern of tumors 
and proliferative activity immunohistochemically in 20 
seminoma cases and found that the growth was between 
50% and 80%. In this study, in which most of the patients’ 
pathologic stages were advanced, there was a relation 
between the tumor pathology and the proliferation rate. 
Since the proliferative activity of seminomas determined 
their sensitivity to chemotherapy and radiation, it is 
advised to look for Ki-67 in these tumors (17). The Ki-67 
index of the patients with seminomas was 35.6 and that of 
NSGCTs was 50.1 in our study. Statistical analysis showed 
no connection between maspin and Ki-67 (P > 0.05).
The p53 tumor suppressor gene located on the 
short limb of the 17th chromosome (17pl31) has many 
mutations (18). p53 overexpression and mutations 
can be seen in many cancers with little differential and 
associated poor prognosis. Bostwich et al. reported 
that p53 immunoreactivity in urothelial carcinomas 
was associated with high tumor stage, degree, vascular 
invasion, recurrence, and progression (19). Since p53 
expression usually coexists with resistance to radiotherapy 
and chemotherapy and the sensitivity of testis GCTs 
to radiotherapy and chemotherapy, whether p53 
protein expression in GCTs is dependent on a mutation 
occurring in the p53 gene has been investigated in many 
studies (20,21). Although studies have reported that p53 
mutations occur in testicular GCTs, other studies have 
reported that the protein expressed in these tumors 
is a wild-type p53 protein (19–21). p53 expression in 
normal cells suggests a good prognosis. However, p53 
overexpression and mutation in tumor cells are associated 
with a poor prognosis (18). p53 staining of seminomas 
and NSGCTs was evaluated separately in this study. Strong 
p53 expression was detected in NSGCTs compared with 
seminomas. This result is important in terms of indicating 
that mutant p53 was expressed much more than in 
NSGCTs with a more aggressive course. In addition, a 
statistically positive relation between maspin and p53 in 
NSGCTs was demonstrated. Maspin may have displayed 
an effect through the p53 pathway in NSGCTs.
CD31 is a molecule in an immunoglobulin superfamily 
weighing 130 kDa and generally one of the most widely 
used markers for measuring vein density, which is the 
arithmetic measurement of tumor angiogenesis (7). In 
a study carried out by Yilmazer et al., CD31 and CD34 
markers were used for measuring microvein density 
(MVD) in renal cell carcinomas (RCCs). Although a 
significant relation was detected between CD34 staining 
and tumor progression, no correlation between CD31 
level and tumor type, stage, nuclear degree, or survival was 
observed (22). However, Turunc et al. showed that MVD 
measured with the CD31 marker was in counter-relation 
to the progression of RCCs and reported that it was a 
good prognostic factor (7). The vein count in five large 
magnification areas for CD31 was calculated in our study, 
and no statistically significant relation was found between 
maspin and CD31 in either seminomas or NSGCTs.
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In conclusion, that maspin was expressed in testicular 
tumors was first shown in this study. Maspin was 
expressed more in NSGCTs compared with seminomas, 
but no relation was observed between maspin and tumor 
stage and size. Thus, it remains unclear whether maspin is 
a poor prognostic factor in testicular tumors. Moreover, 
no connection was observed between maspin and VEGF, 
Ki-67, or CD31. Therefore, maspin might have affected 
testicular tumors through a different method or receptor 
at the cellular level apart from angiogenesis or similar 
pathways. Thus, the fact that a significant relation was 
observed between maspin and p53 makes us think that 
maspin could have an effect via the p53 pathway. To 
discover the mechanism of action of maspin in testicular 
tumors, wider chain studies are needed.
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